In Vitro Diagnostics - Ghana | Statista Market Forecast

The projected revenue for the In Vitro Diagnostics market market in Ghana is estimated to reach US$21.95m in 2024.
It is anticipated that the revenue will experience an annual growth rate (CAGR 2024-2029) of 3.40%, leading to a market volume of US$25.94m by 2029.
When comparing globally, the United States is expected to generate the highest revenue, with US$30.10bn in 2024.
Ghana's In Vitro Diagnostics market is witnessing a growing demand for point-of-care testing devices to improve access to healthcare in remote areas.

Definition:
The market In Vitro Diagnostics (IVD) consists of medical instruments and accessories used to perform tests with the help of biological samples. In Vitro Diagnostics provide valuable information used for detection, prognosis, prevention, and therapeutic monitoring of diseases.

Additional information:
Market values represent revenues paid to primary vendors at manufacturer price level either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), enterprises (B2B) as well as governments (B2G). Revenues are allocated to the country where the money is spent.

Company examples: Roche Diagnostics, Abbott Laboratories, Danaher, Siemens Healthineers.
Further information on the key players can be found in the Market Shares boxes.

Molecular diagnosis
Immunoassays
Clinical chemistry
Microbiology
Hematology

Services (i.e., treatment expenses)
Imaging diagnostics

The In Vitro Diagnostics market in Ghana is experiencing significant growth and development.

Customer preferences: Customers in Ghana are increasingly seeking access to advanced medical technologies and diagnostic tools. They are becoming more aware of the importance of early detection and accurate diagnosis in the treatment of diseases. As a result, there is a growing demand for In Vitro Diagnostics (IVD) products in the country.

Trends in the market: One of the key trends in the IVD market in Ghana is the increasing adoption of point-of-care testing (POCT) devices. These devices allow for rapid and accurate diagnosis at the patient's bedside, reducing the need for laboratory testing and improving patient outcomes. The convenience and efficiency of POCT devices make them particularly appealing in resource-constrained settings like Ghana. Another trend in the market is the growing prevalence of non-communicable diseases (NCDs) in Ghana. Diseases such as diabetes, cardiovascular diseases, and cancer are on the rise, driving the demand for diagnostic tests to monitor and manage these conditions. This trend is expected to further fuel the growth of the IVD market in the country.

Local special circumstances: Ghana has a relatively underdeveloped healthcare infrastructure compared to some other countries in the region. This presents both challenges and opportunities for the IVD market. On one hand, the lack of well-equipped laboratories and trained personnel can hinder the adoption and use of advanced diagnostic technologies. On the other hand, it creates a significant market opportunity for companies that can provide affordable and user-friendly IVD products that can be used in low-resource settings.

Underlying macroeconomic factors: Ghana has been experiencing steady economic growth in recent years, which has contributed to an increase in healthcare spending. The government has been investing in the improvement of healthcare infrastructure and the expansion of healthcare services, including diagnostics. This favorable economic environment, coupled with the rising burden of diseases, has created a conducive market for the growth of the IVD sector in Ghana. In conclusion, the In Vitro Diagnostics market in Ghana is witnessing significant growth and development driven by customer preferences for advanced medical technologies, the increasing adoption of point-of-care testing devices, the growing prevalence of non-communicable diseases, and the favorable macroeconomic factors. The market presents opportunities for companies that can provide affordable and user-friendly IVD products tailored to the local healthcare infrastructure and needs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Medical technology plays a role in the lives of everyone. It includes most of all, medical devices which simplify the prevention, diagnosis, and treatment of diseases and illnesses. The most well-known medical technology products are, among others, pacemakers, imaging instruments, dialysis machines, and implants. The global medical technology industry was worth over 567 billion U.S. dollars annually. Established centers of this industry include North America and Western Europe. The United States is home to the world’s largest medical technology companies. As of 2022, Abbott Laboratories had the largest global revenue at over 31.2 billion U.S. dollars. The main focus of devices manufactured by the Chicago-based company are diagnostics, cardiovascular, and diabetes care. Two other medtech companies that round off the top three largest companies –Medtronic and Johnson & Johnson – are both based in the United States. Although, industry trends show that Asia, and in particular China, is about to play a more prominent role in the years to come.